Progression-Free Survival in Patients With Cholangiocarcinoma With or Without <i>FGF/FGFR</i> Alterations: A FIGHT-202 Post Hoc Analysis of Prior Systemic Therapy Response.

20 The retrospective study by Jain et al reported that the median PFS in patients with FGFR alterations receiving first-line chemotherapy for CCA was numerically longer compared with those without FGFR alterations (33.9 v 25.4 weeks); however, this difference did not reach statistical significance ( P = .07). 13 Another retrospective, observational study based on real-world data from 571 patients with advanced CCA compared OS in patients with FGFR2 fusions/rearrangements versus those without FGFR2 alterations. 21 Although patients were not selected by therapy received or by therapy line, median OS was numerically longer for patients with FGFR2 fusions/rearrangements compared with those without FGFR2 alterations (12.1 v 7.1 months).

also in 111,027 other papers